World Leader in Bench-Top Flow Chemistry Instruments ThalesNano, Inc. Closes Funding Round



    
    Investment to be Used to Accelerate R&D for Continuous Process Chemistry
    Technologies and for Further Global Expansion
    

    BUDAPEST, Hungary and LONDON and PRINCETON, NJ and SAN DIEGO, CA, Sept. 8
/CNW/ - ThalesNano Inc. announced today the closing of an investment of $3.3M
by a group of private and financial investors. The new private investors are
Dominic Gallello, CEO of Graphisoft and Dave Tapolczay, CEO of Medical
Research Council Technology and former VP of GlaxoSmithKline, the second
largest pharmaceutical company worldwide. The proceeds will be used to expand
R&D to further strengthen ThalesNano's leadership position in the development
and implementation of continuous process technologies from research to process
development and full scale production. In addition, the company will expand
commercial operations and services globally with particular emphasis on the US
and Asia and increase production capacity based on the high demand for its
technologies and instruments.
    The benefits of continuous flow technologies over conventional batch
chemistry include the rapid synthesis of organic compounds, in particular
under until now unrealizable hazardous reaction conditions. Further benefits
include Green Chemistry by minimizing waste, energy consumption and raw
material use, lab automation, and rapid scale-up from mg to kg quantities,
which reduces CAPEX and OPEX while speeding time to market.
    Dr. Laszlo Urge, CEO of ThalesNano said, "We are glad that our new
investors clearly see the value creation of our business. We have shown
significant growth over the last year in the core business. In addition,
strategic partnerships were created with major pharmaceutical companies
including Sanofi-Aventis SA to implement continuous process technologies on a
wider scale. As a result of our intensified R&D, we expect our customers to
realize additional benefits in terms of reducing development time, increasing
cost efficiency and minimizing environmental impact."
    Dr. Ferenc Darvas, Chairman of ThalesNano Inc. said, "Our strategy of
providing a disruptive technology to the industry is working and the
confidence shown by our new investors further validates this. Providing
integrated continuous flow solutions from discovery to full scale production
will help to solve some of the key bottlenecks in the pharmaceutical,
biotechnology and chemical industries."
    For more information please go to: http://www.thalesnano.com

    About ThalesNano Inc.:

    ThalesNano is a world-leading provider of continuous process chemistry
instruments in the rapidly developing market of laboratory and process scale
flow reactors. The company has the widest portfolio of bench-top continuous
process instruments. Its R&D 100 award winning H-Cube(R) continuous-flow
hydrogenation reactor and the pilot plant scale version H-Cube Midi(TM) are
used in hundreds of laboratories in four continents and have become the new
industry standard for hydrogenation. 20 out of 20 of the largest
pharmaceutical companies in the world employ ThalesNano products and
technologies.





For further information:

For further information: Laszlo Urge, Ph.D., CEO, e-mail:
ceodirect@thalesnano.com, Telephone: +36-1-880-8500

Organization Profile

THALESNANO INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890